Press release
Schizophrenia Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Schizophrenia Treatment Landscape. Click here to read more @ Schizophrenia Pipeline Outlook [https://www.delveinsight.com/sample-request/schizophrenia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Schizophrenia Pipeline Report
* On 28 August 2025, AbbVie announced a study will assess adverse events, change in disease activity, and how oral emraclidine moves through the body in adult participants with schizophrenia.
* On 22 August 2025, Merck Sharp & Dohme LLC organized a study was to evaluate the efficacy and safety of MK-8189 at a range of doses (8 mg, 16 mg, and 24 mg once daily [QD]) in adult participants who have an acute episode of schizophrenia according to Diagnostic and Statistical Manual of Mental Disorders 5th Edition (DSM-5) criteria. The primary hypotheses were the following: (1) that MK-8189 24 mg is superior to placebo in reducing the Week 6 mean change from baseline in Positive and Negative Syndrome Scale (PANSS) total score, and (2) that MK-8189 16 mg is superior to placebo in reducing the Week 6 mean change from baseline in PANSS total score.
* On 22 August 2025, ACADIA Pharmaceuticals Inc. conducted a Phase 3 study to Evaluate the Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia.
* On 20 August 2025, Bristol-Myers Squibb conducted a phase 3 study With a 5-week Double-blind Part (Randomized, Parallelgroup, Placebo-controlled) Followed by a 52-week Open-label Extension Part to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Patients With Diagnostic and Statistical Manual of Mental Disorders-Fifth Edition (DSM-5) Schizophrenia.
* DelveInsight's Schizophrenia pipeline report depicts a robust space with 55+ active players working to develop 60+ pipeline therapies for Schizophrenia treatment.
* The leading Schizophrenia Companies such as Sunovion Pharmaceuticals, Denovo BioPharma, Karuna Therapeutics, Boehringer Ingelheim, Merck Sharp & Dohme, MapLight Therapeutics, Valentech LLC, Addex Therapeutics, Biodexa Pharmaceuticals, Autifony Therapeutics, Vanda Pharmaceuticals, Luye Pharma, Reviva Pharmaceuticals, SyneuRx, Avanir Pharmaceuticals, Newron Pharmaceuticals, Celon Pharma, Delpor, Zhejiang Jingxin Pharmaceutical, Sirtsei Pharmaceuticals and others.
* Promising Schizophrenia Therapies such as x Brexpiprazole, ICLEPERTIN (BI-425809), KarXT (Xanomeline-Trospium), NUPLAZID (pimavanserin), MK-5720, NaBen, Brilaroxazine (RP-5063), ULOTARONT (SEP-363856), LUVADAXISTAT (NBI 1165844/TAK 831), Roluperidone (MIN-101), BXCL501 80, TV-44749, Evenamide (NW-3509/NW-3509A), LYN-005 (risperidone, weekly), OKEDI (risperidone ISM), Emraclidine (CVL-231), and others.
Stay informed about the cutting-edge advancements in Schizophrenia treatments. Download for updates and be a part of the revolution in cancer care @ Schizophrenia Clinical Trials Assessment [https://www.delveinsight.com/sample-request/schizophrenia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Schizophrenia Emerging Drugs Profile
* Ulotaront: Sunovion Pharmaceuticals
SEP-363856 is a TAAR1 agonist with 5-HT1A agonist activity that is under investigation for the treatment of schizophrenia and other psychiatric conditions. Sunovion discovered SEP-363856 in collaboration with PsychoGenics based in part on a mechanism-independent approach using the in vivo phenotypic SmartCube platform and associated artificial intelligence algorithms. Research has shown that ulotaront results in a greater reduction from baseline in the PANSS total score than placebo. Treatment with ulotaront, as compared with placebo, was also associated with an improvement in sleep quality. Currently, the drug is in the Phase III stage of its development for the treatment of Schizophrenia
* Emraclidine: Abbvie
Emraclidine is a selective M4 receptor PAM, meaning it selectively targets the M4 receptor to harness the anti-psychotic effect believed to be associated with this receptor while minimizing the side effects associated with other pan-muscarinic agonists. The company believes emraclidine has the potential to provide a significant medical advancement as the muscarinic acetylcholine pathway has long been associated with mediation of neurotransmitter imbalance and psychosis. Emraclidine is the only selective M4 receptor PAM currently in clinical development. Currently, the drug is in the Phase II stage of its development for the treatment of Schizophrenia.
* CY 6463: Cyclerion Therapeutics
CY6463 is the first CNS-penetrant sGC stimulator to be developed as a symptomatic and potentially disease-modifying therapy for serious CNS diseases. The nitric oxide (NO)-soluble guanylate cyclase (sGC)-cyclic guanosine monophosphate (cGMP) signaling pathway is a fundamental mechanism that precisely controls key aspects of physiology throughout the body. As an sGC stimulator, CY6463 acts as a positive allosteric modulator to sensitize the sGC enzyme to NO, increase the production of cGMP, and thereby amplify endogenous NO signaling. By compensating for deficient NO-sGC-cGMP signaling, CY6463 and other sGC stimulators may have broad therapeutic potential as a treatment to improve cognition and function in people with serious CNS diseases. Currently, the drug is in the Phase I stage of its development for the treatment of Schizophrenia.
Learn more about Schizophrenia Drugs opportunities in our groundbreaking Schizophrenia Research and development projects @ Schizophrenia Unmet Needs [https://www.delveinsight.com/sample-request/schizophrenia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Schizophrenia Companies
Sunovion Pharmaceuticals, Denovo BioPharma, Karuna Therapeutics, Boehringer Ingelheim, Merck Sharp & Dohme, MapLight Therapeutics, Valentech LLC, Addex Therapeutics, Biodexa Pharmaceuticals, Autifony Therapeutics, Vanda Pharmaceuticals, Luye Pharma, Reviva Pharmaceuticals, SyneuRx, Avanir Pharmaceuticals, Newron Pharmaceuticals, Celon Pharma, Delpor, Zhejiang Jingxin Pharmaceutical, Sirtsei Pharmaceuticals and others.
Schizophrenia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Intravenous
* Subcutaneous
* Oral
* Intramuscular
Schizophrenia Products have been categorized under various Molecule types such as
* Monoclonal antibody
* Small molecule
* Peptide
Discover the latest advancements in Schizophrenia treatment by visiting our website. Stay informed about how we're transforming the future of neurology @ Schizophrenia Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/schizophrenia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Schizophrenia Pipeline Report
* Coverage- Global
* Schizophrenia Companies- Sunovion Pharmaceuticals, Denovo BioPharma, Karuna Therapeutics, Boehringer Ingelheim, Merck Sharp & Dohme, MapLight Therapeutics, Valentech LLC, Addex Therapeutics, Biodexa Pharmaceuticals, Autifony Therapeutics, Vanda Pharmaceuticals, Luye Pharma, Reviva Pharmaceuticals, SyneuRx, Avanir Pharmaceuticals, Newron Pharmaceuticals, Celon Pharma, Delpor, Zhejiang Jingxin Pharmaceutical, Sirtsei Pharmaceuticals and others.
* Schizophrenia Therapies- Brexpiprazole, ICLEPERTIN (BI-425809), KarXT (Xanomeline-Trospium), NUPLAZID (pimavanserin), MK-5720, NaBen, Brilaroxazine (RP-5063), ULOTARONT (SEP-363856), LUVADAXISTAT (NBI 1165844/TAK 831), Roluperidone (MIN-101), BXCL501 80, TV-44749, Evenamide (NW-3509/NW-3509A), LYN-005 (risperidone, weekly), OKEDI (risperidone ISM), Emraclidine (CVL-231), and others
* Schizophrenia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Schizophrenia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Schizophrenia Pipeline on our website @ Schizophrenia Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/schizophrenia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Schizophrenia: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Schizophrenia- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* LYN-005: Lyndra Therapeutics
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Emraclidine: Abbvie
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* KYN-5356: Kynexis
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Schizophrenia Key Companies
* Schizophrenia Key Products
* Schizophrenia- Unmet Needs
* Schizophrenia- Market Drivers and Barriers
* Schizophrenia- Future Perspectives and Conclusion
* Schizophrenia Analyst Views
* Schizophrenia Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=schizophrenia-pipeline-outlook-2025-clinical-trial-studies-ema-pdma-fda-approvals-moa-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/schizophrenia-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Schizophrenia Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies here
News-ID: 4163916 • Views: …
More Releases from ABNewswire
Red Teaming vs Penetration Testing: Understanding the Difference
Image: https://www.abnewswire.com/upload/2025/12/bc1e8a773c50dd0c9305d06207de098f.jpg
The topic of red teaming vs penetration testing often creates confusion among security teams, decision-makers and technical stakeholders. Both approaches aim to uncover weaknesses, yet they work in very different ways. Many organisations rely on one method thinking it covers the role of the other. This misunderstanding can lead to gaps in visibility, unclear expectations and misplaced confidence.
A clearer view of pentest vs red team helps organisations make better…
Suburban Solutions Moving Announces New West Chester, PA Location to Strengthen …
West Chester, PA - Suburban Solutions [https://suburbansolutions.com/], a highly trusted and fast-growing moving company serving the Greater Philadelphia and Washington, DC regions, is proud to announce the opening of its newest location at 1271 Upton Cir, West Chester, PA 19380. This expansion marks an important step in the company's ongoing mission to provide dependable and accessible relocation support to more communities across Pennsylvania.
With this new branch, Suburban Solutions Moving aims…
LSLONG Launches New Premium Custom Polo Shirt Collection with Full OEM & ODM Sup …
Shenzhen LSLONG Garments Co., Ltd., a global leader in apparel manufacturing, has officially unveiled its new Premium Custom Polo Shirt [https://www.lslt-shirt.com/polo-shirt-categories/] Collection, combining advanced fabrics, innovative designs, and end-to-end customization solutions. This launch underscores LSLONG's 25 years of experience delivering high-quality OEM and ODM apparel services to brands across more than 50 countries. The collection aims to empower brands with versatile, stylish, and performance-driven Polo shirts while providing comprehensive support…
Arteestry Creations Plus Brings Unique Customizable Designs to Over 50 Product C …
Arteestry Creations Plus offers creative custom designs across an extensive range of products from apparel to home goods to magnets, serving customers seeking personalized items for holidays, special occasions, and everyday use. The growing e-commerce brand combines artistic creativity with broad product versatility, featuring licensed collections from Disney, Pixar, Marvel, and Star Wars alongside original designs that can be applied across different product types upon customer request.
Arteestry Creations Plus has…
More Releases for Schizophrenia
Rising Mental Illness Burden Fuels Growth In The Schizophrenia Market: Critical …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Schizophrenia Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The financial scope of the schizophrenia market has shown consistent expansion lately, projected to see an increase from a valuation of $5.82 billion in 2024 to $6.06 billion by 2025, reflecting a compound annual growth rate…
Rising Mental Illness Burden Fuels Growth In The Schizophrenia Market: Pivotal F …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts
Schizophrenia Market Size Growth Forecast: What to Expect by 2025?
In the past few years, the schizophrenia market size has seen robust growth. The projected growth from $5.82 billion in 2024 to $6.11 billion in 2025, signifies a compound annual growth rate (CAGR) of 5.0%. Factors such as increased…
Schizophrenia Drugs Market Opportunity | Size | Research Report
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲: Schizophrenia Drugs Market was valued at USD 5.3 Billion in 2018 and is projected to reach USD 8.42 Billion by 2026, growing at a CAGR of 3.66% from 2019 to 2026.
Market Overview for Schizophrenia Drugs Market
Schizophrenia Drugs Market OverviewThe schizophrenia drugs market is experiencing significant growth driven by advancements in pharmacotherapy and increasing awareness about mental health disorders. Schizophrenia, a chronic and severe mental disorder affecting millions…
Schizophrenia Drugs Market - Restoring Balance, Inspiring Hope: Schizophrenia Dr …
Newark, New Castle, USA: The "Schizophrenia Drugs Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Schizophrenia Drugs Market: https://www.growthplusreports.com/report/schizophrenia-drugs-market/7871
This latest report researches the industry structure, sales, revenue,…
Schizophrenia Drugs Market - Leading the Way in Schizophrenia Treatment: Nurturi …
Newark, New Castle, USA - new report, titled Schizophrenia Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Schizophrenia Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Schizophrenia Drugs market. The report offers an overview of the market, which…
Schizophrenia Drug Market & Pipeline Insight
Schizophrenia is defined as a disorder of the brain which impacts the way in which a person acts, thinks, and sees the world. It has been observed that the patients suffering from schizophrenia generally tend to have an altered perception of reality, which reveals a significant diversion from the reality. In most cases, schizophrenia is diagnosed among people in the late teens or early adulthood. However, middle-aged people also could…
